Clinical trials: Central Line
Non-Small Cell Lung Cancer
Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
This is a clinical research study to evaluate if chemotherapy in the experimental arm (E) results in a better outcome compared to patients in the standard of care arm (C).
- Trial name
- NCT00499109
- Testing
- Docetaxel, Vinorelbine, Carboplatin
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 275 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma of the Head and Neck
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of…
- Trial name
- KESTREL (NCT02551159)
- Testing
- MEDI4736, Tremelimumab, MEDI4736+Tremelimumab
- Where
- 197 sites in United States, Austria and 21 more
- Volunteers
- 823 people
- Sponsor
- AstraZeneca
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Central Line Complication, Neonatal Disease
Impact of Cyanoacrylate Glue on PICC Line Dressing Care
This study will evaluate whether applying micro drops of cyanoacrylate glue to the participant's peripherally inserted central catheter (PICC) insertion site prior to covering the area of PICC line with a transparent film…
- Trial name
- NCT05246709
- Testing
- Cyanoacrylate glue, Standard transparent film dressing
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Columbia University
RRMM
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
This is a randomized, two-period, cross-over Phase 2 study, comparing PK, and assessing safety and tolerability and efficacy of peripheral and central intravenous administration of melflufen in patients with RRMM.
- Trial name
- PORT (NCT04412707)
- Testing
- Melphalan, Dexamethasone
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 27 people
- Sponsor
- Oncopeptides AB
Chronic Myelogenous Leukemia
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
- Trial name
- NCT04948333
- Testing
- ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD
- Where
- 48 sites in Argentina, Austria and 14 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Infection
Community Central Line Infection Prevention Trial
The overall goal of this Community Central Line Infection Prevention (CCLIP) trial, supported by grant R01 HS022870 from the Agency for Healthcare Research and Quality, is to determine whether use of a promising new intervention…
- Trial name
- CCLIP (NCT02351258)
- Testing
- 70% Isopropyl alcohol embedded caps, Usual Care
- Where
- 16 sites in United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Thrombosis
Pediatric Catheter-related Thrombosis Imaging Study
This protocol will serve as a pilot study to determine the validity and feasibility of contrast enhanced magnetic resonance imaging (MRI) without and with contrast and/or ultrasound (US) for detection of catheter related deep…
- Trial name
- AESOP (NCT01137578)
- Testing
- Ultrasound, Magnetic Resonance Imaging with Contrast, Magnetic Resonance Imaging without Contrast
- Where
- 26 sites in United States, Argentina and 7 more
- Volunteers
- 151 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer NSCLC
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients…
- Trial name
- ORION (NCT03775486)
- Testing
- Durvalumab, Olaparib, Nab-paclitaxel+carboplatin
- Where
- 68 sites in United States, Belgium and 10 more
- Volunteers
- 401 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV…
- Trial name
- NCT00718523
- Testing
- AMG 479
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 170 people
- Sponsor
- Translational Research in Oncology
No Specific Conditions Under Study. Primary Focus: Adult Subjects Who Require PICC Placement
Assessment of the Precision of the Sherlock 3CG Tip Positioning System
Phase I determine the location of the peripherally inserted central catheter (PICC) tip upon observation of maximum p-wave amplitude Phase II determine the precision of PICC placement in the Sherlock 3CG group versus the standard…
- Trial name
- STAT-PICC (NCT01275430)
- Testing
- Sherlock 3CG, Blind Placement
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- C. R. Bard
Central Line Catheters
Central Venous Access Study
The aim of this study is to document clinicians variation in practice in comparison to standard guidelines by the Medical Center's approved Evidence-based Practice (EBP) guidelines, policies, and procedures for Central Venous…
- Trial name
- CASCADE (NCT03480542)
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- Hackensack Meridian Health
Lung Cancer
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
This is an open label Phase II Trial that using the investigational anti-cancer agent, Pazopanib to see whether non-squamous non-small cell lung cancer will respond to its use by decreasing the size of the tumor or stopping its…
- Trial name
- LCCC0921 (NCT01262820)
- Testing
- Pazopanib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chest Wrinkles
Evaluation of the Ulthera System for the Treatment of the Decolletage
This is prospective, multi-center clinical trial. Enrolled subjects will receive one Ulthera® treatment on the decolletage. Follow-up visits will occur at 90 and 180 days following treatment.
- Trial name
- NCT01713686
- Testing
- Ulthera System Treatment
- Where
- 4 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Ulthera, Inc
Biliary Tract Cancer
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.
- Trial name
- NCT04163900
- Testing
- NUC-1031, Gemcitabine, Cisplatin
- Where
- 125 sites in United States, Australia and 13 more
- Volunteers
- 773 people
- Sponsor
- NuCana plc
Neoplasms, Breast
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
This study investigates the safety and efficacy of oral lapatinib in combination with an approved medication, paclitaxel, for patients with ErbB2 metastatic breast cancer.
- Trial name
- NCT00356811
- Testing
- Lapatinib oral tablets, Paclitaxel infusion
- Where
- 13 sites in Latvia, Poland and 2 more
- Volunteers
- 57 people
- Sponsor
- GlaxoSmithKline
Kidney Failure, Chronic, Catheter-Related Infections
Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
The purpose of this study is determine safety and effectiveness of Neutrolin, a catheter lock solution, for prevention of central venous catheter associated bloodstream infection in hemodialysis patients.
- Trial name
- NCT02651428
- Testing
- Neutrolin, Heparin
- Where
- 5 sites in United States
- Volunteers
- 806 people
- Sponsor
- CorMedix Therapeutics
Facial Rhytides, Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
This study evaluated the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of forehead lines (facial rhytides) when also administered to frown lines (glabellar rhytides).
- Trial name
- NCT01391299
- Testing
- botulinum toxin Type A, Normal Saline
- Where
- Canada
- Volunteers
- 175 people
- Sponsor
- Allergan
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
This is a Phase 1b/2 multi-center, open-label study to establish the initial safety and to determine a recommended Phase 2 dose of B-701 in combination with pembrolizumab, and to determine safety, tolerability and efficacy of…
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Trial name
- FIERCE-22 (NCT03123055)
- Testing
- B-701, Pembrolizumab
- Where
- 52 sites in United States, Belgium and 15 more
- Volunteers
- 28 people
- Sponsor
- Rainier Therapeutics
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi